Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...
November 13, 2025 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026CNTY-308...
November 13, 2025 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate...
October 14, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...
August 22, 2025 08:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
August 14, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Reports Q2 2025 Results and Business Update
May 28, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
May 15, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and...
April 28, 2025 16:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived...
April 15, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived...